Impact of COPD Treatment on Survival in Patients with Advanced Non-Small Cell Lung Cancer

Hyunji Jo; Sojung Park; Nam Eun Kim; So Young Park; Yon Ju Ryu; Jung Hyun Chang; Jin Hwa Lee

doi:10.3390/jcm11092391

Impact of COPD Treatment on Survival in Patients with Advanced Non-Small Cell Lung Cancer

Hyunji Jo, Sojung Park, Nam Eun Kim, So Young Park, Yon Ju Ryu, Jung Hyun Chang, Jin Hwa Lee

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Chronic obstructive pulmonary disease (COPD) is associated with a poor prognosis in patients with non-small cell lung cancer (NSCLC). However, the impact of COPD treatment on the survival of patients with advanced NSCLC remains uncertain. We retrospectively investigated COPD patients among patients newly diagnosed with advanced NSCLC between September 2005 and August 2019 at a university hospital. The clinical characteristics, lung function, and survival outcomes were analyzed and compared between patients who did and did not receive COPD treatment. Among 221 patients with advanced NSCLC and COPD, 124 patients received treatment for COPD and 97 patients did not receive treatment for COPD. Forced expiratory volume in 1 s (FEV₁ ) % predicted value was greater in the no-treatment group than in the COPD treatment group (p < 0.001). The median overall survival (OS) of the treatment group was 10.7 months, while that of the no-treatment group was 8.7 months (p = 0.007). In the multivariate analysis, COPD treatment was independently associated with improved OS (hazard ratio 0.71, 95% confidence interval 0.53–0.95, and p = 0.021). COPD treatment was associated with improved OS in patients with advanced NSCLC and COPD. Therefore, pretreatment spirometry and maximal treatment for COPD may offer a chance of optimal management for patients with advanced NSCLC.

Original language	English
Article number	2391
Journal	Journal of Clinical Medicine
Volume	11
Issue number	9
DOIs	https://doi.org/10.3390/jcm11092391
State	Published - 1 May 2022

Bibliographical note

Funding Information:
Funding: This work was supported by the National Research Foundation of Korea (NRF-2020R1A5A2019210). The funding source had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.

Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.

Keywords

bronchodilator
chronic obstructive pulmonary disease
inhaled corticosteroids
non-small cell lung cancer
survival

Access to Document

10.3390/jcm11092391

Cite this

@article{db91d80105f4493a98656c58c130f3f6,

title = "Impact of COPD Treatment on Survival in Patients with Advanced Non-Small Cell Lung Cancer",

abstract = "Chronic obstructive pulmonary disease (COPD) is associated with a poor prognosis in patients with non-small cell lung cancer (NSCLC). However, the impact of COPD treatment on the survival of patients with advanced NSCLC remains uncertain. We retrospectively investigated COPD patients among patients newly diagnosed with advanced NSCLC between September 2005 and August 2019 at a university hospital. The clinical characteristics, lung function, and survival outcomes were analyzed and compared between patients who did and did not receive COPD treatment. Among 221 patients with advanced NSCLC and COPD, 124 patients received treatment for COPD and 97 patients did not receive treatment for COPD. Forced expiratory volume in 1 s (FEV1 ) % predicted value was greater in the no-treatment group than in the COPD treatment group (p < 0.001). The median overall survival (OS) of the treatment group was 10.7 months, while that of the no-treatment group was 8.7 months (p = 0.007). In the multivariate analysis, COPD treatment was independently associated with improved OS (hazard ratio 0.71, 95% confidence interval 0.53–0.95, and p = 0.021). COPD treatment was associated with improved OS in patients with advanced NSCLC and COPD. Therefore, pretreatment spirometry and maximal treatment for COPD may offer a chance of optimal management for patients with advanced NSCLC.",

keywords = "bronchodilator, chronic obstructive pulmonary disease, inhaled corticosteroids, non-small cell lung cancer, survival",

author = "Hyunji Jo and Sojung Park and Kim, {Nam Eun} and Park, {So Young} and Ryu, {Yon Ju} and Chang, {Jung Hyun} and Lee, {Jin Hwa}",

note = "Funding Information: Funding: This work was supported by the National Research Foundation of Korea (NRF-2020R1A5A2019210). The funding source had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results. Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = may,

day = "1",

doi = "10.3390/jcm11092391",

language = "English",

volume = "11",

journal = "Journal of Clinical Medicine",

issn = "2077-0383",

publisher = "MDPI AG",

number = "9",

}

TY - JOUR

T1 - Impact of COPD Treatment on Survival in Patients with Advanced Non-Small Cell Lung Cancer

AU - Jo, Hyunji

AU - Park, Sojung

AU - Kim, Nam Eun

AU - Park, So Young

AU - Ryu, Yon Ju

AU - Chang, Jung Hyun

AU - Lee, Jin Hwa

N1 - Funding Information: Funding: This work was supported by the National Research Foundation of Korea (NRF-2020R1A5A2019210). The funding source had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results. Publisher Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2022/5/1

Y1 - 2022/5/1

N2 - Chronic obstructive pulmonary disease (COPD) is associated with a poor prognosis in patients with non-small cell lung cancer (NSCLC). However, the impact of COPD treatment on the survival of patients with advanced NSCLC remains uncertain. We retrospectively investigated COPD patients among patients newly diagnosed with advanced NSCLC between September 2005 and August 2019 at a university hospital. The clinical characteristics, lung function, and survival outcomes were analyzed and compared between patients who did and did not receive COPD treatment. Among 221 patients with advanced NSCLC and COPD, 124 patients received treatment for COPD and 97 patients did not receive treatment for COPD. Forced expiratory volume in 1 s (FEV1 ) % predicted value was greater in the no-treatment group than in the COPD treatment group (p < 0.001). The median overall survival (OS) of the treatment group was 10.7 months, while that of the no-treatment group was 8.7 months (p = 0.007). In the multivariate analysis, COPD treatment was independently associated with improved OS (hazard ratio 0.71, 95% confidence interval 0.53–0.95, and p = 0.021). COPD treatment was associated with improved OS in patients with advanced NSCLC and COPD. Therefore, pretreatment spirometry and maximal treatment for COPD may offer a chance of optimal management for patients with advanced NSCLC.

AB - Chronic obstructive pulmonary disease (COPD) is associated with a poor prognosis in patients with non-small cell lung cancer (NSCLC). However, the impact of COPD treatment on the survival of patients with advanced NSCLC remains uncertain. We retrospectively investigated COPD patients among patients newly diagnosed with advanced NSCLC between September 2005 and August 2019 at a university hospital. The clinical characteristics, lung function, and survival outcomes were analyzed and compared between patients who did and did not receive COPD treatment. Among 221 patients with advanced NSCLC and COPD, 124 patients received treatment for COPD and 97 patients did not receive treatment for COPD. Forced expiratory volume in 1 s (FEV1 ) % predicted value was greater in the no-treatment group than in the COPD treatment group (p < 0.001). The median overall survival (OS) of the treatment group was 10.7 months, while that of the no-treatment group was 8.7 months (p = 0.007). In the multivariate analysis, COPD treatment was independently associated with improved OS (hazard ratio 0.71, 95% confidence interval 0.53–0.95, and p = 0.021). COPD treatment was associated with improved OS in patients with advanced NSCLC and COPD. Therefore, pretreatment spirometry and maximal treatment for COPD may offer a chance of optimal management for patients with advanced NSCLC.

KW - bronchodilator

KW - chronic obstructive pulmonary disease

KW - inhaled corticosteroids

KW - non-small cell lung cancer

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85128747700&partnerID=8YFLogxK

U2 - 10.3390/jcm11092391

DO - 10.3390/jcm11092391

M3 - Article

AN - SCOPUS:85128747700

SN - 2077-0383

VL - 11

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

IS - 9

M1 - 2391

ER -

Impact of COPD Treatment on Survival in Patients with Advanced Non-Small Cell Lung Cancer

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this